Biomarkers in Pulmonary Hypertension Associated to Interstitial Lung Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Charlotte Andersen, University of Aarhus
ClinicalTrials.gov Identifier:
NCT00820729
First received: January 9, 2009
Last updated: September 17, 2012
Last verified: September 2012
  Purpose

The presence of an abnormally increased pulmonary blood pressure worsens the prognosis of patients with interstitial pulmonary disease.

The aim of this study is to estimate the frequency of an increased blood pressure in the lungs among patient with interstitial pulmonary disease, and to evaluate the use of different biomarkers in diagnosis of the condition.


Condition
Interstitial Lung Disease
Pulmonary Hypertension
Biomarkers

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: The Prevalence of Pulmonary Hypertension and the Significance of Different Biomarkers in Chronic Interstitial Lung Disease

Resource links provided by NLM:


Further study details as provided by University of Aarhus:

Biospecimen Retention:   Samples With DNA

blood samples


Enrollment: 212
Study Start Date: March 2009
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients with interstitial pulmonary disease

Detailed Description:

The presence of increased pulmonary blood pressure is established by echocardiography and confirmed by right heart catheterization.

The ability of NT-proBNP, vWf, troponin-t, D-dimer and exhaled NO to predict the presence of increased pressure in the pulmonary circulation is evaluated.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Out-patients with interstitial pulmonary disease.

Criteria

Inclusion Criteria:

  • Interstitial pulmonary disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00820729

Locations
Denmark
Department of Pulmonary Diseases, Århus Sygehus
Århus, Denmark, Dk-8000
Department of Cardiology, Skejby sygehus
Århus N, Denmark, DK-8200
Sponsors and Collaborators
University of Aarhus
  More Information

No publications provided

Responsible Party: Charlotte Andersen, MD, University of Aarhus
ClinicalTrials.gov Identifier: NCT00820729     History of Changes
Other Study ID Numbers: Fibrosis-ECHO 2009
Study First Received: January 9, 2009
Last Updated: September 17, 2012
Health Authority: Denmark: Ethics Committee

Keywords provided by University of Aarhus:
interstitial lung disease
pulmonary hypertension
biomarkers
NT-pro-BNP
von Willebrand factor
D-dimer
Exhaled NO
Troponin-t

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Lung Diseases
Lung Diseases, Interstitial
Vascular Diseases
Cardiovascular Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 15, 2014